Drug intelligence / Profile preview

Sishen Wan

Development stage: Unknown
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**Sishen Wan** (also known as Sishen Pill or Four Miracle Pill) is a classic traditional Chinese medicine (TCM) formula first recorded during the Song and Ming dynasties. It is traditionally indicated for 'cock-crow' or early-morning diarrhea caused by Spleen and Kidney Yang deficiency. The formula consists of four primary herbal ingredients—*Psoralea corylifolia* (Bu Gu Zhi), *Myristica fragrans* (Rou Dou Kou), *Evodia rutaecarpa* (Wu Zhu Yu), and *Schisandra chinensis* (Wu Wei Zi)—classically prepared with fresh ginger (*Zingiber officinale*) and jujube (*Ziziphus jujuba*). Modern pharmacological research indicates that Sishen Wan alleviates gastrointestinal disorders, such as diarrhea-predominant irritable bowel syndrome (IBS-D) and ulcerative colitis, by improving intestinal barrier integrity, regulating endoplasmic reticulum stress, promoting autophagy, and restoring gut microbiota balance. It is widely manufactured and marketed in China as an over-the-counter (OTC) and prescription proprietary Chinese medicine.

Brand names: Tong Ren Tang Sishen PillsTong Ren Tang Sishen WanTongrentang Sishen PillsTongrentang Sishen Wan
Other names: Four Miracle PillFour Spirits FormulaFour Spirits PillRoudou Sishen PillRoudou Sishen WanSi Shen WanSishen PillSishen-Wan四神丸

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)MAPK14 (p38 mitogen-activated protein kinase alpha)NF-κBSTAT3 (Signal Transducer and Activator of Transcription 3)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))BCL-2 (BCL-2 family)HSP90AA1 (Heat shock protein HSP90-alpha)IL-6 (Interleukin 6)MAPK3 (Mitogen-activated protein kinase 1)MYD88 (Myeloid differentiation primary response protein MyD88)

Beyond the preview

Go deeper on Sishen Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sishen Wan.